Rebound after MAPK inhibitor withdrawal in pLGG cells
An in vitro MAPK inhibitor withdrawal rebound model was generated using the patient-derived, PXA-like cell line BT-40 (BRAFV600E, CDKN2Adel). Using this model, we investigated potential cellular intrinsic and extrinsic mechanisms involved in rebound growth in pLGG through multi-omics analysis (RNAseq, phospho-/proteomics). Overall design: To investigate molecular mechanisms up-/downregulated upon MAPKi treatment and withdrawal, BT-40 cells were treated for 5 days with 5 nM dabrafenib, followed by up to 72h of treatment withdrawal. Five days treatment with DMSO (solvent) serves a control